News | July 06, 2022
CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Amarex Clinical Research guides its client to phase II of FDA trials
New Director supports NASDAQ rule on diversity
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Subscribe To Our Newsletter & Stay Updated
